You’ve probably seen the claim: Dihexa is “millions of times more potent than BDNF.” It’s the kind of statement that sounds either revolutionary or like complete nonsense — and your instinct to be skeptical is correct.
Dihexa is the most hyped and least proven compound in the cognitive peptide space. And its story includes something most promoters don’t mention: the foundational research has been seriously compromised. Here’s the full picture, including what most sources won’t tell you.
Dihexa
Synthetic Hexapeptide (HGF/c-Met activator)
Also known as: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide
Evidence Summary
- Strongest evidence for:
- Nothing qualifies as “strong” — all evidence is preclinical.
- Promising but early:
- HGF/c-Met pathway activation for neural connectivity (animal models only)
- Mostly anecdotal:
- Cognitive enhancement in healthy adults (community reports only)
- Key limitation:
- Zero published human trials exist. Foundational research by Dr. Joseph Harding has been compromised — one key paper retracted, multiple others under investigation. The “millions of times more potent than BDNF” claim comes from this compromised research. All claims about human cognitive enhancement are community anecdotal reports.
What It Is
Dihexa is a synthetic hexapeptide designed to activate the HGF/c-Met receptor system, which is involved in neural connectivity and synapse formation. It was developed at Washington State University. The original research claimed extraordinary potency in promoting cognitive function in animal models. However, the foundational researcher (Dr. Joseph Harding) has had key research retracted and other papers investigated for data integrity concerns. This doesn’t necessarily mean the compound doesn’t work — but it means the evidence base consumers are relying on is compromised at its foundation.
What the Research Says
HGF/c-Met Activation
T3: Early / AnecdotalAnimal studies showed enhanced cognitive function and neural connectivity through activation of the HGF/c-Met receptor system, which is involved in synapse formation. But the primary researcher’s work has been called into question, so the magnitude of the reported effect should be treated with skepticism.
Typical Protocol
| Route | Oral or sublingual (typically) |
| Dosage Range | Varies widely in community reports — no clinical standard exists |
| Frequency | No established protocol |
| Time to Effect | Unknown — no controlled data |
| Note | No established clinical protocol exists. Community-reported dosing is not medically validated. |
Protocols vary by individual. Always follow your prescribing provider's instructions.
Risks & Side Effects
- Unknown — no human safety studies.
- Potential HGF/c-Met pathway risks including theoretical cancer concern (HGF/c-Met is implicated in tumor progression).
- Long-term effects completely unknown.
- This is the highest-uncertainty compound on our site.
Who Should Not Consider Dihexa
If you have a cancer history or active malignancy: The HGF/c-Met pathway that Dihexa activates is implicated in tumor progression. This is not a theoretical concern — it is a known oncology issue. HGF/c-Met inhibitors are an area of active cancer drug development precisely because activation of this pathway promotes tumor growth and metastasis. Anyone with a personal cancer history should not consider Dihexa.
If you are pregnant or breastfeeding: No safety data exists. Absolute contraindication.
If you are not comfortable with compromised foundational research: Dihexa’s mechanism story rests on research from a lab that has had a key paper retracted and other papers under investigation. If you can’t make peace with that as a foundation for what you put in your body, that is a reasonable position — and Dihexa is not the right compound for you.
If you are unwilling to accept high uncertainty: This is the least-proven compound on our site. Zero human trials. Compromised preclinical work. Unstudied long-term safety. If you want a peptide where the evidence supports confident decision-making, this is not it.
If this is your first cognitive peptide: Don’t start here. Semax and Selank have substantially stronger evidence profiles, longer track records, and better-characterized safety. If you’re new to cognitive peptides, those are the right starting points.
Legal & Access Status
Category 2 — expected Category 1. Not PCAC-referred.
Before You Start: Get Baseline Labs
We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include IGF-1, fasting glucose, CBC, CMP and a thyroid panel.
Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.
Lab recommendations are the same regardless of which service you use. See how we make money.
Questions for Your Provider
- 1Are you familiar with the retraction issues surrounding Dihexa’s foundational research?
- 2Given the lack of human trials, what is your clinical rationale for prescribing this?
- 3How do you assess the HGF/c-Met pathway cancer risk?
- 4What monitoring would you recommend?
- 5Have you seen results in your patients, and how do you distinguish that from placebo?
Find a Provider
We’re finalizing our vetted provider list. Subscribe to be notified when provider recommendations go live.
When provider links go live, we’ll disclose all affiliate relationships here. See how we make money.
Stay ahead of the FDA.
Regulatory updates as developments happen. New compound profiles weekly. No spam. No sales pitches.